The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Series B | Alive

Total Raised


Last Raised

$12.3M | 5 yrs ago

About Teewinot Life Sciences

Teewinot Life Sciences is a global biopharmaceutical company focused on the biosynthetic production of pure pharmaceutical grade cannabinoids. Teewinot has developed patent-protected processes for the production of pure cannabinoids by means of biocatalysis and synthetic biology, all with the goal of improving human therapies. Teewinot manufactures and licenses technology that reduces cost and production time, increases purity of cannabinoids, and diversifies the number and types of molecules which can be made available to the research, product development, and commercial production verticals.

Teewinot Life Sciences Headquarter Location

13033 W. Linebaugh Ave.

Tampa, Florida, 33626,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Teewinot Life Sciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Teewinot Life Sciences is included in 2 Expert Collections, including Synthetic Biology.


Synthetic Biology

305 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.



3,834 items

These companies participate in - or service businesses that participate in - the legal cannabis industry. Our definition of cannabis includes both marijuana and hemp (and all derivatives). The collection includes both "plant-touching" and "non-plant-touching" businesses.

Teewinot Life Sciences Patents

Teewinot Life Sciences has filed 1 patent.

The 3 most popular patent topics include:

  • Benzochromenes
  • Cannabinoids
  • Designer drugs
patents chart

Application Date

Grant Date


Related Topics




Cannabinoids, Designer drugs, Phenols, JWH cannabinoids, Benzochromenes


Application Date


Grant Date



Related Topics

Cannabinoids, Designer drugs, Phenols, JWH cannabinoids, Benzochromenes



Latest Teewinot Life Sciences News

Teewinot Life Sciences to Participate at the 31st Annual Piper Jaffray Healthcare Conference in New York

Nov 25, 2019

| Source: Teewinot Life Sciences Corporation TAMPA, Fla., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Teewinot Life Sciences Corporation (“Teewinot” or the “Company”), a global leader in the biosynthetic production of cGMP cannabinoids and cannabinoid analogs as new chemical entities, today announced Michael Luther Ph.D., Chief Executive Officer, will participate on the Future of Cannabinoid Biosynthesis Panel at the 31st Annual Piper Jaffray Healthcare Conference in New York being held from December 3rd – 5th, 2019 at the Lotte New York Palace. Panel Details: Time:               3:00 – 3:55 PM ET Location:         Villard Room, Lotte New York Palace For anyone interested in arranging a one-on-one meeting at the event, please contact the bank’s representative or the Company’s investor relations department. About Teewinot Life Sciences Teewinot Life Sciences is a global leader in the biosynthetic development and production of cannabinoids and their derivatives for consumer and pharmaceutical products. The Company is leveraging a unique integrated biocatalytic and chemical synthesis platform, that allows the production of an unprecedented range of cannabinoids and cannabinoid NCEs from bench to cGMP manufacturing. This platform supports Teewinot’s drug discovery programs as well as industry partnerships for pharmaceutical and consumer product development. Teewinot is revolutionizing the synthetic cannabinoid space with its cost-effective, commercial scale approach to meet the global growing demand for cannabinoid-based products to address unmet health, wellness, and therapeutic needs. About CannSynthesis® CannSynthesis® is the world’s only patent-protected biocatalytic process for the production of rare cannabinoids from bench to cGMP commercial scale. It utilizes a modular approach for bioreactions to produce specific rare cannabinoids at high titer and purity with high efficiency and speed. The biocatalytic process is complemented with a variety of proprietary chemical transformations to convert the biologically-derived cannabinoids into other rare cannabinoids. Today, this platform allows for Teewinot to deliver the widest and most diverse range of cannabinoids for the growing market demand. Forward Looking Statements Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes or benefits are forward- looking statements. A number of risks and uncertainties, such as risks related to product development and commercialization efforts, ultimate clinical outcomes and benefit of the Company’s products, market acceptance of the Company’s products, intellectual property protection, competitive product offerings, adverse changes in the public perception of cannabis, adverse changes in applicable laws and adverse changes in the application or enforcement of current laws, could cause actual events to differ from the expectations indicated in these forward-looking statements. You are cautioned not to put any undue reliance on any forward-looking statement. This press release is neither an offer to sell nor a solicitation of an offer to purchase any particular securities. Any such offer or solicitation will be made only pursuant to definitive legal agreements prepared specifically for such purpose. An investment in the Company’s securities entails significant risks and is suitable only for sophisticated investors who can afford a loss of their entire investment; no assurance can be given that investment objectives will be achieved. In considering the information contained herein, you should bear in mind that past performance is not necessarily indicative of future results; there can be no assurance that the Company will achieve comparable results or that any projected returns will be met. The Company does not assume any obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events, or otherwise. Contact:

Teewinot Life Sciences Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Teewinot Life Sciences Rank

  • Where is Teewinot Life Sciences's headquarters?

    Teewinot Life Sciences's headquarters is located at 13033 W. Linebaugh Ave., Tampa.

  • What is Teewinot Life Sciences's latest funding round?

    Teewinot Life Sciences's latest funding round is Series B.

  • How much did Teewinot Life Sciences raise?

    Teewinot Life Sciences raised a total of $19.3M.

  • Who are the investors of Teewinot Life Sciences?

    Investors of Teewinot Life Sciences include Tuatara Capital.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.